Tarnawski A, Arakawa T, Kobayashi K
VA Medical Center, Long Beach, California 90822, USA.
Dig Dis Sci. 1998 Sep;43(9 Suppl):90S-98S.
Rebamipide (Mucosta) is a novel mucosal protective and ulcer-healing drug. Clinical and experimental data indicate that it accelerates ulcer healing and improves the quality of the scar. Since epidermal growth factor (EGF) and its receptor (EGF-R) play important roles in mucosal protection and ulcer healing, we studied whether rebamipide treatment affects expression of EGF and EGF-R in normal and ulcerated gastric mucosa in rats. Forty-eight male rats without or with gastric ulcers (induced by acetic acid) received intragastrically either placebo or rebamipide, 40 mg twice daily, for 14 days. Ulcer size was measured under a dissecting microscope; mucosal sections were stained with H&E or immunostained with specific antibodies against EGF and EGF-R. The distribution and intensity of fluorescence signal was quantified using a video image system. Rebamipide significantly accelerated ulcer healing, produced a significant increase in EGF and EGF-R expression in normal gastric mucosa (both P < 0.001), and increased expression of EGF and EGF-R in regenerating glands of the ulcer scar. Since EGF and its receptor are crucial for epithelial cell proliferation, re-epithelialization, and gland reconstruction, the above actions of rebamipide may provide a new mechanism for its ulcer healing action.
瑞巴派特（膜固思达）是一种新型的黏膜保护和溃疡愈合药物。临床和实验数据表明，它能加速溃疡愈合并改善瘢痕质量。由于表皮生长因子（EGF）及其受体（EGF-R）在黏膜保护和溃疡愈合中起重要作用，我们研究了瑞巴派特治疗是否会影响大鼠正常和溃疡胃黏膜中EGF和EGF-R的表达。48只无胃溃疡或有胃溃疡（由乙酸诱导）的雄性大鼠，分别经胃内给予安慰剂或瑞巴派特（40mg，每日两次），持续14天。在解剖显微镜下测量溃疡大小；黏膜切片用苏木精-伊红染色或用抗EGF和EGF-R的特异性抗体进行免疫染色。使用视频图像系统对荧光信号的分布和强度进行定量。瑞巴派特显著加速溃疡愈合，使正常胃黏膜中EGF和EGF-R的表达显著增加（均P<0.001），并使溃疡瘢痕再生腺中EGF和EGF-R的表达增加。由于EGF及其受体对上皮细胞增殖、再上皮化和腺体重建至关重要，瑞巴派特的上述作用可能为其溃疡愈合作用提供一种新机制。
